Melanotan II

II. What is this compound?

Strip away the controversy and MT-II is a piece of molecular mimicry. It's a cyclic heptapeptide — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, roughly 1024.2 daltons — built as a superpotent, metabolically stabilized analogue of α-melanocyte-stimulating hormone (α-MSH), one of the melanocortin peptides the body derives from the proopiomelanocortin (POMC) precursor.

Its defining trait — and what separates it from descendant PT-141 PT-141 cyclic heptapeptide lactam / melanocortin receptor agonist Melanocortin receptor agonist studied for sexual desire, arousal & CNS-mediated erectile function — is non-selectivity across the entire melanocortin receptor family. Where bremelanotide focuses comparatively on the MC3R/MC4R sexual-function receptors, MT-II activates the whole panel: MC1R (pigmentation), MC3R and MC4R (appetite and sexual function), and MC5R [3] PMID: 17584134 . One switch, several circuits — which is why tanning, appetite suppression, and sexual arousal arrive together, along with a correspondingly wide side-effect profile.

The original ambition was photoprotection: stimulate MC1R on epidermal melanocytes, drive eumelanin synthesis, and build a UV-independent tan that might, in theory, reduce sun-seeking behavior and skin-cancer risk [4] PMID: 8637535 . Whether that theory survives contact with the dermatology evidence is one of this page's central questions.

III. How it works

The core mechanism of Melanotan II is broad, non-selective activation of melanocortin receptors — think of it as a master key that fits every lock in the family, with each receptor subtype explaining a different part of the effect profile.

MC1R activation drives the pigmentation the peptide was designed for. On epidermal melanocytes, MC1R signaling upregulates eumelanin production, darkening skin without requiring UV-induced DNA damage as the trigger [5] PMID: 8637535 . The tan appears within days of dosing and can persist for weeks — far outlasting the peptide's brief circulation.

MC3R and MC4R activation in the hypothalamus mediates the sexual-function effects. Central melanocortin signaling in arousal circuits — the same paraventricular-nucleus pathways later exploited therapeutically by bremelanotide — produces erections and increased sexual desire [6] PMID: 9474129 . This was the observation that reframed everything: a tanning peptide revealed a brain-level lever on sexual arousal [7] PMID: 15992957 .

MC4R activation also suppresses appetite, consistent with the established role of hypothalamic melanocortin tone in energy balance. Reduced food intake is a predictable pharmacological consequence, not an incidental quirk.

The unifying theme: MT-II's effects cannot be cleanly separated. You cannot activate the pigmentation pathway without also engaging the arousal, appetite, and cardiovascular melanocortin circuits — the fundamental pharmacological reason a more selective successor, PT-141 PT-141 cyclic heptapeptide lactam / melanocortin receptor agonist Melanocortin receptor agonist studied for sexual desire, arousal & CNS-mediated erectile function , was pursued for sexual medicine, and the thread the next section follows into the evidence itself.

• Non-selective agonism across melanocortin receptors (MC1R, MC3R, MC4R, MC5R) — unlike the more MC3R/MC4R-selective metabolite bremelanotide (PT-141)
  PMID 17584134
• MC1R activation on epidermal melanocytes stimulates eumelanin synthesis (melanogenesis), producing skin darkening independent of UV exposure
  PMID 8637535
• Central MC3R/MC4R activation in hypothalamic circuits mediates erectile and sexual-arousal responses — the effect that redirected melanocortin research toward sexual dysfunction and led to bremelanotide
  PMID 9474129PMID 15992957

IV. Research Findings

Honesty first, because marketing rarely provides it: the evidence base for Melanotan II is thin, early-phase, and decades old. No large, modern controlled trials support its use, and no regulator has judged its benefit-risk balance acceptable.

For skin pigmentation, the support comes from small phase-I academic work. Early University of Arizona studies demonstrated that subcutaneous MT-II produced measurable, UV-independent tanning — genuine proof of concept for melanocortin-driven photoprotection [8] PMID: 8637535 . What those studies never established is long-term safety, an appropriate dose, or whether induced pigmentation meaningfully reduces skin-cancer risk in practice.

For sexual function, the data are phase-II and historically pivotal but limited. A double-blind, placebo-controlled crossover study reported that MT-II initiated erections in men with psychogenic erectile dysfunction, and a follow-up examined organic erectile dysfunction and sexual desire [9] PMID: 9474129 [10] PMID: 10792262 . These results proved a central melanocortin mechanism for erection — and then the development baton passed to the more selective metabolite bremelanotide, precisely because MT-II's broad activity and side effects made it unsuitable as a therapeutic.

That handoff is the real takeaway: Melanotan II's chief legacy is scientific rather than clinical, a mechanism discovery its safer, approved successor now exploits. Which raises the practical question of dosing — and why this compound has no answer to give.

• skin-pigmentation-tanning phase_1_clinical
  PMID 8637535
• erectile-function phase_2_clinical
  PMID 9474129PMID 10792262

V. Dosage Context Explained

There is no validated, safe human dose of Melanotan II — and nothing here should be read as a dosing recommendation. The compound is not an approved medicine, and product sold online is unlicensed, of unknown purity, and often mislabeled.

The only human figures in the literature come from small academic studies, where supervised subcutaneous MT-II was administered at roughly 0.025 mg/kg — about 2 mg for an 80 kg adult — under clinical oversight [11] PMID: 8637535 . Those numbers describe what researchers used decades ago in a controlled setting; they say nothing about the vial of unknown concentration actually circulating online, and that gap is precisely where harm occurs.

Two structural problems make 'dosing' MT-II uniquely hazardous: - Non-selectivity: any dose that produces tanning also engages the appetite, sexual, and cardiovascular melanocortin circuits. - Supply risk: because selling it for human use is illegal, there is no quality control on purity, sterility, or actual peptide content.

For anyone weighing the underlying goals, the responsible framing points two directions: the pigmentation objective does not justify this safety profile, and the sexual-function objective has a better-served, approved route — the successor explored on our PT-141 PT-141 cyclic heptapeptide lactam / melanocortin receptor agonist Melanocortin receptor agonist studied for sexual desire, arousal & CNS-mediated erectile function page.

• Administration Routes

  subcutaneous

  Range

  reported in early studies at roughly 0.025 mg/kg; consumer use is unstandardized and unverified

  Dosing figures come from small academic studies and are NOT a recommendation. There is no validated safe dose for human use, and product purity in the unregulated market is unknown.

  PMID 8637535

VI. Side Effects: Research Context

Melanotan II's side-effect profile is the reason it never became a medicine — and the reason regulators keep issuing warnings about it.

Acute effects are common. Nausea and facial flushing showed up frequently even in early supervised dosing, and spontaneous penile erections were a recurring finding in male subjects — a direct consequence of central melanocortin activation, not a fluke [12] PMID: 8637535 [13] PMID: 9474129 .

The pigmentary risks are the most serious. Beyond generalized darkening of skin, lips, and gums, dermatology case literature describes darkening, enlargement, and rapid change of existing moles, plus the appearance of new melanocytic naevi in people using melanotan products. Because changing moles are a cardinal warning sign monitored for melanoma, this is no cosmetic footnote: it complicates skin-cancer surveillance, and a personal or family history of melanoma or atypical naevi is a strong reason to avoid the compound. These reports come from published case series — treat the association as a documented safety signal rather than a quantified risk.

Priapism — a prolonged, painful erection — has been reported and qualifies as a urological emergency capable of permanent damage when untreated.

Supply-side harm stacks on top of the pharmacology. Because MT-II is sold illegally and unregulated, injected product may be non-sterile, contaminated, or of unknown concentration — infection and overdose risk layered onto the compound's intrinsic effects. Regulators have read this ledger the same way, as the legal picture makes clear.

• nausea and facial flushing (frequently observed in early clinical dosing)
• spontaneous penile erections in male subjects
• darkening and rapid change of existing moles and new melanocytic naevi (raising melanoma-surveillance concerns — reported in dermatology case literature)
• priapism (prolonged, painful erection — reported in case reports, a urological emergency)
• generalized hyperpigmentation, including of lips, gums and skin folds
• risk of unsterile/contaminated product and injection-related infection in the unregulated supply

VII. Frequently Asked Questions